|1.||Wolf, Myles: 33 articles (10/2015 - 08/2008)|
|2.||Fukumoto, Seiji: 19 articles (04/2015 - 07/2003)|
|3.||Isakova, Tamara: 17 articles (10/2015 - 08/2008)|
|4.||Jüppner, Harald: 16 articles (02/2014 - 04/2003)|
|5.||Gutiérrez, Orlando M: 13 articles (05/2015 - 08/2008)|
|6.||Imanishi, Yasuo: 12 articles (10/2014 - 05/2002)|
|7.||White, Kenneth E: 11 articles (07/2014 - 04/2003)|
|8.||Fukagawa, Masafumi: 11 articles (01/2014 - 08/2004)|
|9.||Econs, Michael J: 10 articles (03/2014 - 04/2003)|
|10.||Fujita, Toshiro: 8 articles (08/2012 - 10/2005)|
|1.||X-Linked Dominant Hypophosphatemic Rickets (X-Linked Hypophosphatemia)
11/15/2011 - "Autosomal dominant hypophosphatemic rickets (ADHR) is unique among the disorders involving Fibroblast growth factor 23 (FGF23) because individuals with R176Q/W and R179Q/W mutations in the FGF23 (176)RXXR(179)/S(180) proteolytic cleavage motif can cycle from unaffected status to delayed onset of disease. "
10/01/2015 - "We report on a boy who presented with hypophosphatemic rickets with elevated serum fibroblast growth factor 23 (FGF23) and polyostotic osteolytic lesions at age 2 years. "
02/01/2014 - "Fibroblast growth factor 23 (FGF23) gain of function mutations can lead to autosomal dominant hypophosphatemic rickets (ADHR) disease onset at birth, or delayed onset following puberty or pregnancy. "
01/01/2013 - "Fibroblast growth factor 23 (FGF23) is responsible for phosphate wasting and the phenotypic changes observed in human diseases such as X-linked hypophosphatemia (XLH). "
12/01/2012 - "X-linked hypophosphatemia is the most common of the phosphate-wasting disorders mediated by elevated fibroblast growth factor 23 (FGF23) and occurs as a consequence of inactivating mutations of the PHEX gene product. "
05/20/2014 - "[Clinical usefulness of the determination of fibroblast growth factor 23 in the evaluation of patients with osteomalacia]."
01/01/2008 - "Sporadic adult-onset hypophosphatemic osteomalacia caused by excessive action of fibroblast growth factor 23."
01/01/2008 - "Serum fibroblast growth factor 23 was the upper limit of normal despite extreme hypophosphatemia and no neoplastic lesion potentially inducing hypophosphatemic osteomalacia could be identified in a thorough search including imaging studies of his entire body. "
04/01/2015 - "Osteomalacia induced by a phosphaturic mesenchymal tumor secreting fibroblast growth factor 23."
08/01/2014 - "Tumor-induced osteomalacia (TIO) is a disease caused by fibroblast growth factor 23 (FGF23) secreted from the causative tumor. "
12/01/2015 - "These tumors produce fibroblast growth factor 23, which is implicated in renal tubule phosphate loss. "
12/01/2015 - "These tumors characteristically secrete fibroblast growth factor 23 (FGF23). "
04/01/2015 - "18F-fluorodeoxyglucose positron emission tomography (FDG-PET) depicted the location of the occult tumor, and systemic venous sampling followed by assessments of the samples' fibroblast growth factor 23 (FGF23) concentrations confirmed that the tumor secreted FGF23. "
02/01/2013 - "Tumors secreting fibroblast growth factor 23 are often small and difficult to find with conventional imaging. "
01/01/2012 - "It arises due to the secretion of fibroblast growth factor 23 (FGF-23) from causative tumors. "
|4.||Kidney Diseases (Kidney Disease)
10/01/2015 - "The aim of this study was to evaluate the association of serum intact fibroblast growth factor 23 (FGF23) concentrations with indexed left ventricular mass in children with non-dialysis stages 3-5 of chronic kidney disease (CKD). "
09/01/2007 - "Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study."
07/01/2015 - "Elevated fibroblast growth factor 23 (FGF-23) concentrations are associated with greater risk of cardiovascular events and mortality, especially among people with chronic kidney disease (CKD). "
01/01/2015 - "Fibroblast growth factor 23 predicts coronary calcification and poor prognosis in patients with chronic kidney disease stages 3-5D."
11/01/2014 - "Among the various non-traditional cardiovascular risk factors present in patients with chronic kidney disease, abnormalities of CKD related mineral and bone disorder, which includes elevated fibroblast growth factor 23 (FGF23) have been one of the most extensively studied. "
|5.||Chronic Kidney Failure (Chronic Renal Failure)
10/01/2015 - "Observational studies report independent associations between elevated serum phosphate and fibroblast growth factor 23 (FGF23) levels and risks of ESRD, CVD, and death. "
04/01/2014 - "There is growing evidence that fibroblast growth factor 23 (FGF23) and Klotho factor play a key role in the development of coronary artery calcification in ESRD. "
08/01/2012 - "Elevated levels of fibroblast growth factor 23 are independently associated with mortality in patients with CKD and ESRD. "
11/01/2011 - "Fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality in patients with ESRD. "
06/15/2011 - "Elevated fibroblast growth factor 23 was independently associated with significantly higher risk of end-stage renal disease among participants with an estimated GFR between 30 and 44 mL/min/1.73 m(2) (HR, 1.3 per SD of FGF-23 natural log-transformed FGF-23; 95% CI, 1.04-1.6) and 45 mL/min/1.73 m(2) or higher (HR, 1.7; 95% CI, 1.1-2.4), but not less than 30 mL/min/1.73 m(2). "
|2.||Sodium-Phosphate Cotransporter Proteins (Sodium-Phosphate Cotransporter)
|4.||Parathyroid Hormone (Parathormone)
|1.||Renal Dialysis (Hemodialysis)
|3.||Transplantation (Transplant Recipients)